Deutsche Bank Aktiengesellschaft Boosts GSK (LON:GSK) Price Target to GBX 1,675

GSK (LON:GSK) had its price target increased by investment analysts at Deutsche Bank Aktiengesellschaft from GBX 1,600 to GBX 1,675 in a research report issued to clients and investors on Thursday, Marketbeat reports. The firm presently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential downside of 6.89% from the company’s previous close.

GSK has been the topic of several other research reports. Shore Capital restated a “buy” rating on shares of GSK in a research report on Thursday, January 8th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th. Finally, Berenberg Bank lifted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of GBX 1,807.

GSK Stock Performance

GSK traded down GBX 49 during midday trading on Thursday, hitting GBX 1,799. 754,445,125 shares of the company were exchanged, compared to its average volume of 74,638,578. The company’s 50 day simple moving average is GBX 1,816.90 and its 200 day simple moving average is GBX 1,613.50. The firm has a market capitalization of £72.57 billion, a price-to-earnings ratio of 13.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,909.73. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, sell-side analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds purchased 1,650 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker acquired 441 shares of GSK stock in a transaction on Friday, December 19th. The shares were bought at an average price of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.